
Hepatocellular carcinoma is the most common type of liver cancer. It is an aggressive (fast-growing) cancer that most commonly affects persons with severe liver disease, such as cirrhosis. People with HCC are increasingly being diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD), which can develop to cirrhosis.
Tumours may not present symptoms in their early stages. However, as HCC proceeds, you may notice the following:
Causes
Risk Factors
The following conditions enhance your risk of developing HCC:
There are various ways to lower your chance of having HCC. You can do:
Surgery: The surgical treatments for HCC are hepatectomy (removal of the diseased section of the liver) or liver transplantation.
{liver-transplant}Ablation therapy: This involves the use of a specialised needle to burn malignancies. The needle can direct highly hot energy (microwaves or radiofrequency waves) or extremely cold.
Embolisation: This is the process of implanting a material directly into the arteries that supply the tumour, blocking blood flow.
Radiation therapy: Providers may recommend radiation therapy to treat tiny cancers that cannot be removed surgically or destroyed through ablation.
Immunotherapy: Immunotherapy drugs are also used to treat advanced HCC. They help your immune system recognise and combat cancer cells.
{immunotherapy}Targeted therapy: These medications treat advanced HCC. This medication inhibits the signal that tells cancer cells to continue growing.
Cost Start From USD 5500 - USD 54000Explore Options
Hepatocellular Carcinoma (HCC) rehabilitation treatments aim to increase quality of life, accelerate physical recovery, and minimise therapeutic side effects. Here are the main rehabilitation alternatives for HCC patients:
MediGence can assist and guide you in selecting the best physician and medical facility for your care.
Depending on the circumstances, your doctor may prescribe medication to assist you in managing your symptoms and support your treatment plan.
Treatment regimens are adapted to the patient's specific cancer stage and location.









Ajman, United Arab Emirates
Thumbay University Hospital, Ajman located in Ajman, United Arab Emirates is accredited by JCI. Also listed below are some of the most prominent infrastructural details:
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Here are some of the reasons for choosing United Arab Emirates:
In the United Arab Emirates, liver transplantation is a viable therapy option for hepatocellular carcinoma (HCC), particularly for patients with cirrhosis, liver tumours, and early-stage malignancy. Numerous respectable transplant centres in the United Arab Emirates perform successful liver transplants and offer complete care.
In the United Arab Emirates, hepatocellular carcinoma (HCC) is effectively treated, especially when caught early. UAE hospitals use cutting-edge therapy to achieve exceptional patient outcomes.
The nation's sophisticated equipment, highly skilled specialists, and comprehensive treatment programs result in higher survival rates and improved quality of life for patients receiving treatment for HCC.
In the United Arab Emirates, hepatocellular carcinoma (HCC) is effectively treated, especially when caught early. UAE hospitals use cutting-edge therapy to achieve exceptional patient outcomes.
The nation's sophisticated equipment, highly skilled specialists, and comprehensive treatment programs result in higher survival rates and improved quality of life for patients receiving treatment for HCC.
Yes, lifestyle changes include:
Hepatocellular carcinoma (HCC) is less common in the United Arab Emirates than in East Asia and Sub-Saharan Africa. The incidence rate is very low. One of the main risk factors is the prevalence of chronic hepatitis B and C virus infections in the United Arab Emirates. Reducing the prevalence of HCC in the United Arab Emirates requires constant monitoring and management of these risk factors.
According to developments in treatments like liver transplants, surgery, and customised medications, many patients can maintain a high quality of life. However, the impact of the condition differs according to the stage of the malignancy and available treatments.